Becton Dickinson 향후 성장

Future 기준 점검 1/6

Becton Dickinson (는) 각각 연간 14.8% 및 2.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 14.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 19.2% 로 예상됩니다.

핵심 정보

14.8%

이익 성장률

14.67%

EPS 성장률

Medical Equipment 이익 성장	13.3%
매출 성장률	2.9%
향후 자기자본이익률	19.23%
애널리스트 커버리지	Good
마지막 업데이트	07 Nov 2025

최근 향후 성장 업데이트

Recent updates

Becton, Dickinson and Company: Strong Earnings But Murky Outlook

Nov 07

Becton, Dickinson and Company: It's Wait And See For Me

Apr 27

Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline

Mar 30

Beckton, Dickinson: Hold, Momentum Is Gaining, Just Need More Growth

Jan 20

Statutory Profit Doesn't Reflect How Good Becton Dickinson's (NYSE:BDX) Earnings Are

Dec 04

이익 및 매출 성장 예측

NYSE:BDX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
9/30/2028	23,608	2,789	4,212	5,181	6
9/30/2027	23,351	2,346	3,924	4,912	14
9/30/2026	22,540	2,046	3,626	3,812	14
9/30/2025	21,840	1,678	2,670	3,430	N/A
6/30/2025	21,386	1,585	2,550	3,254	N/A
3/31/2025	20,867	1,498	2,591	3,300	N/A
12/31/2024	20,640	1,727	2,936	3,650	N/A
9/30/2024	20,178	1,705	3,073	3,798	N/A
6/30/2024	19,828	1,459	3,221	3,944	N/A
3/31/2024	19,716	1,364	3,025	3,760	N/A
12/31/2023	19,492	1,265	2,649	3,431	N/A
9/30/2023	19,372	1,470	2,115	2,989	N/A
6/30/2023	19,046	1,582	1,743	2,638	N/A
3/31/2023	18,809	1,556	1,009	1,966	N/A
12/31/2022	18,738	1,486	1,361	2,359	N/A
9/30/2022	18,870	1,545	1,661	2,634	N/A
6/30/2022	18,958	1,412	1,465	2,575	N/A
3/31/2022	18,924	1,430	2,041	3,141	N/A
12/31/2021	18,534	1,079	2,620	3,751	N/A
9/30/2021	19,131	1,514	3,453	4,647	N/A
6/30/2021	19,066	1,486	4,222	5,177	N/A
3/31/2021	18,313	1,379	4,150	5,064	N/A
12/31/2020	18,207	1,507	3,476	4,359	N/A
9/30/2020	16,074	245	2,728	3,497	N/A
6/30/2020	16,917	786	2,474	3,429	N/A
3/31/2020	17,414	923	2,509	3,499	N/A
12/31/2019	17,355	760	2,835	3,798	N/A
9/30/2019	17,290	1,081	2,373	3,330	N/A
6/30/2019	17,108	784	N/A	3,265	N/A
3/31/2019	17,036	926	N/A	2,875	N/A
12/31/2018	17,063	894	N/A	2,790	N/A
9/30/2018	15,983	159	N/A	2,865	N/A
6/30/2018	14,747	621	N/A	2,685	N/A
3/31/2018	13,503	-99	N/A	2,527	N/A
12/31/2017	12,251	294	N/A	2,555	N/A
9/30/2017	12,093	1,030	N/A	2,550	N/A
6/30/2017	12,158	759	N/A	2,129	N/A
3/31/2017	12,321	1,314	N/A	2,579	N/A
12/31/2016	12,419	1,309	N/A	2,411	N/A
9/30/2016	12,483	976	N/A	2,559	N/A
6/30/2016	12,312	1,139	N/A	2,532	N/A
3/31/2016	12,234	810	N/A	2,236	N/A
12/31/2015	11,217	688	N/A	1,907	N/A
9/30/2015	10,282	695	N/A	1,730	N/A
6/30/2015	9,410	815	N/A	1,591	N/A
3/31/2015	8,448	1,079	N/A	1,492	N/A
12/31/2014	8,468	1,150	N/A	1,677	N/A

애널리스트 향후 성장 전망

수입 대 저축률: BDX 의 연간 예상 수익 증가율(14.8%)이 saving rate(3.3%)보다 높습니다.

수익 vs 시장: BDX 의 연간 수익(14.8%)이 US 시장(16%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: BDX 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: BDX 의 수익(연간 2.9%)이 US 시장(연간 10.4%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: BDX 의 수익(연간 2.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: BDX의 자본 수익률은 3년 후 19.2%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/11/09 02:59
종가	2025/11/07 00:00
수익	2025/09/30
연간 수익	2025/09/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Becton, Dickinson and Company는 34명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Charles Butler	Barclays
Matthew Miksic	Barclays

Becton Dickinson 향후 성장

Future 기준 점검 1/6

핵심 정보

최근 향후 성장 업데이트

Becton, Dickinson and Company Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Fiscal Ended September 30, 2025

Becton, Dickinson and Company Revises Its Earnings Guidance for the Year 2025

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 10%

Price target decreased by 16% to US$231

Becton, Dickinson and Company Updates Earnings Guidance for the Fiscal Year 2025

Recent updates

New minor risk - Earnings quality

Becton, Dickinson and Company: Strong Earnings But Murky Outlook

Full year 2025 earnings: EPS misses analyst expectations

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on December 31, 2025

Becton, Dickinson and Company Achieves Milestone in AGILITY Study of Revello Vascular Covered Stent for Treatment of Peripheral Artery Disease

BD Receives FDA 510(k) Clearance and CE-IVDR Certification for High-Throughput Enteric Bacterial Panels on BD COR System

Becton, Dickinson and Company Announces New Self- Collection Solution for HPV Testing in Markets Outside the United States

Bd Introduces the Bd Incada™? Connected Care Platform

Becton, Dickinson and Company Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Fiscal Ended September 30, 2025

Becton, Dickinson and Company Reaches Major Milestone for Rotarex™? Catheter System with First Patient Enrolled in XTRACT™? Registry to Advance Real-World Evidence in Peripheral Artery Disease

Bd Marks 1,000Th Bd Rhapsody System, Driving Scientific Breakthroughs Via Single-Cell Multiomics

Upcoming dividend of US$1.04 per share

Director recently bought US$1.0m worth of stock

Third quarter 2025 earnings: EPS exceeds analyst expectations

Becton, Dickinson and Company Revises Its Earnings Guidance for the Year 2025

Becton, Dickinson and Company Submits Application to FDA for At-Home Hpv Test with Self-Collection Swab and High-Tech Laboratory Robotics

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Rapid Point-Of-Care COVID-19 Test

Second quarter dividend of US$1.04 announced

Becton, Dickinson and Company Announces First Pharma-Sponsored Clinical Trial Using BD Libertas Wearable Injector Technology for Biologic Drugs

Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion.

BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment, Effective July 2

Consensus EPS estimates fall by 12%

Upcoming dividend of US$1.04 per share

Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex™? Atherectomy System in Treatment of Peripheral Artery Disease

Retractable Technologies, Inc. Enters Settlement Agreement with Becton, Dickinson and Company

Becton, Dickinson and Company Announces Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'

Becton, Dickinson and Company Launches Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies

Consensus EPS estimates fall by 10%

Price target decreased by 16% to US$231

Second quarter dividend of US$1.04 announced

Becton, Dickinson and Company Updates Earnings Guidance for the Fiscal Year 2025

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2025

Becton, Dickinson and Company: It's Wait And See For Me

Becton, Dickinson and Company Launches Industry-First Bioabsorbable Mesh Designed for Umbilical Hernia Repair

Becton, Dickinson and Company Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with Ai-Driven Clinical Decision Support

Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline

Becton, Dickinson and Company Appoints Gregory J. Hayes to Board of Directors, Effective March 26, 2025

Becton, Dickinson and Company Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery

Becton, Dickinson and Company Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2025

Starboard Value Urges Spinoff of Becton Dickinson

Fourth quarter dividend of US$1.04 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 31, 2025

Beckton, Dickinson: Hold, Momentum Is Gaining, Just Need More Growth

Becton, Dickinson and Company Appoints Pamela Spikner as Senior Vice President, Chief Accounting Officer and Controller, Effective January 20, 2025

Becton, Dickinson and Company, Annual General Meeting, Jan 28, 2025

Statutory Profit Doesn't Reflect How Good Becton Dickinson's (NYSE:BDX) Earnings Are

Upcoming dividend of US$1.04 per share

New major risk - Financial position

Full year 2024 earnings: EPS misses analyst expectations

Becton, Dickinson and Company Q4: Shifting To High-Growth Areas

Third quarter dividend of US$1.04 announced

Now 21% undervalued after recent price drop

Becton, Dickinson and Company Has Declares A Quarterly Dividend, Payable on December 31, 2024

Becton, Dickinson and Company Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Upcoming dividend of US$0.95 per share

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Becton, Dickinson And Company: Somewhat Undervalued, A Very Moderate Buy

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Second quarter dividend of US$0.95 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024

Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024